Phase 3 Clinical Trials Support STELARA® (ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Phase 3 Clinical Trials Support STELARA® (ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
STELARA® is a subcutaneously administered biologic approved by the US Food and Drug Administration in September 2009 for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. This Clinical Brief summarizes the 2 phase 3 multicenter, randomized, double-blind, placebo-controlled trials that demonstrated the efficacy and safety of STELARA®.
More like this
- Unmet Needs in the Management of Plaque Psoriasis
- Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis
- Treating Psoriasis as a T-Cell Mediated Disease
- Managed Care Best Practices In the Treatment and Management of Psoriasis
- Review of the Clinical Information for SIMPONI™ (golimumab) In Rheumatoid Arthritis